Lorazepam Use Linked to Shorter PFS, OS in Several Cancers
Lorazepam use may impact progression-free survival and overall survival in patients with a range of cancers, new research suggests.
Lorazepam use may impact progression-free survival and overall survival in patients with a range of cancers, new research suggests.
Relapse-free survival should not be used as a surrogate for overall survival in cancer trials testing adjuvant immunotherapy, according to researchers.
Adding stereotactic body radiation therapy to immune checkpoint inhibitor therapy was safe but failed to improve progression-free and overall survival.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
More than twofold increased risk of prostate cancer seen for men with first melanoma diagnosed 10 to 15 years before study recruitment
Some disparities that existed before FDA approval persisted after approval, and some new disparities emerged after FDA approval.
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
The use of steroids for the treatment of immune-related adverse events may have survival consequences.
Key changes include new N category descriptors, more stage III subgroups, new M1D designation.
The findings showed that only 29.1% of the skin cancers started in moles patients already had.